{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:45:43Z","timestamp":1793151943316,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M752024"],"award-info":[{"award-number":["2024M752024"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2020CR1032B"],"award-info":[{"award-number":["SHDC2020CR1032B"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016983","name":"Shanghai Clinical Research Center","doi-asserted-by":"publisher","award":["23J41900100"],"award-info":[{"award-number":["23J41900100"]}],"id":[{"id":"10.13039\/501100016983","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["202040400"],"award-info":[{"award-number":["202040400"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130004"],"award-info":[{"award-number":["82130004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670176"],"award-info":[{"award-number":["81670176"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070204"],"award-info":[{"award-number":["82070204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400225"],"award-info":[{"award-number":["82400225"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC2502600"],"award-info":[{"award-number":["2022YFC2502600"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ebiom.2025.105693","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T08:00:17Z","timestamp":1744272017000},"page":"105693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Molecular heterogeneity of CD30+ peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre study"],"prefix":"10.1016","volume":"115","author":[{"given":"Yu-Jia","family":"Huo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Mei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Hui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Ling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Min","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ci","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ran","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Mei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-1616","authenticated-orcid":false,"given":"Wei-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ebiom.2025.105693_bib1","first-page":"47","article-title":"The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management","volume":"70","author":"Marchi","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105693_bib2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105693_bib3","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.ebiom.2025.105693_bib4","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood.2023021789","article-title":"Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs)","volume":"144","author":"Moskowitz","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105693_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511","article-title":"CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy","volume":"85","author":"Falini","year":"1995","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ebiom.2025.105693_bib6","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105693_bib7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17474086.2021.1955344","article-title":"The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas","volume":"14","author":"Karube","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105693_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","volume":"7","author":"van der Weyden","year":"2017","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105693_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41408-022-00644-2","article-title":"Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication","volume":"12","author":"Huo","year":"2022","journal-title":"Blood Cancer J"},{"issue":"5151","key":"10.1016\/j.ebiom.2025.105693_bib10","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"issue":"25","key":"10.1016\/j.ebiom.2025.105693_bib11","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2014-07-588434","article-title":"A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders","volume":"124","author":"Velusamy","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105693_bib12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma","volume":"27","author":"Crescenzo","year":"2015","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105693_bib13","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105693_bib14","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.3324\/haematol.2018.205880","article-title":"DUSP22-rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK\/STAT surrogate markers","volume":"104","author":"Onaindia","year":"2019","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105693_bib15","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3324\/haematol.2012.081935","article-title":"CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features","volume":"98","author":"Bisig","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105693_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2013.10","article-title":"Loss of TCR-beta F1 and\/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas","volume":"3","author":"Rodr\u00edguez-Pinilla","year":"2013","journal-title":"Blood Cancer J"},{"issue":"10168","key":"10.1016\/j.ebiom.2025.105693_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105693_bib18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"28","key":"10.1016\/j.ebiom.2025.105693_bib19","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ebiom.2025.105693_bib20","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105693_bib21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/his.14850","article-title":"Clinicopathological and molecular features of indolent natural killer-cell lymphoproliferative disorder of the gastrointestinal tract","volume":"82","author":"Yi","year":"2023","journal-title":"Histopathology"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105693_bib22","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1097\/PAS.0000000000001315","article-title":"Application of a 5 marker panel to the routine diagnosis of peripheral T-cell lymphoma with T-follicular helper phenotype","volume":"43","author":"Basha","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105693_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.semdp.2019.12.002","article-title":"Pathology and genetics of anaplastic large cell lymphoma","volume":"37","author":"Leventaki","year":"2020","journal-title":"Semin Diagn Pathol"},{"issue":"13","key":"10.1016\/j.ebiom.2025.105693_bib24","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2006-04-017632","article-title":"Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study","volume":"108","author":"Dupuis","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105693_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00432-024-05702-9","article-title":"Role of plasma EBV-DNA load and EBER status on newly diagnosed peripheral T-cell lymphoma","volume":"150","author":"Chen","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ebiom.2025.105693_bib26","article-title":"Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes","author":"Huang","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105693_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105693_bib28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq--a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105693_bib29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105693_bib30","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","article-title":"Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures","volume":"11","author":"Kotlov","year":"2021","journal-title":"Cancer Discov"},{"issue":"43","key":"10.1016\/j.ebiom.2025.105693_bib31","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1016\/j.ebiom.2025.105693_bib32","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2025.105693_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105693_bib34","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","article-title":"An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules","volume":"154","author":"Basu","year":"2013","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.ebiom.2025.105693_bib35","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood.2023021787","article-title":"New insights into the biology of T-cell lymphomas","volume":"144","author":"Iqbal","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105693_bib36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13148-021-01187-2","article-title":"H3K36 trimethylation-mediated biological functions in cancer","volume":"13","author":"Xiao","year":"2021","journal-title":"Clin Epigenetics"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105693_bib37","doi-asserted-by":"crossref","first-page":"128","DOI":"10.21037\/atm-20-7574","article-title":"Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity","volume":"9","author":"Zhong","year":"2021","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105693_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2021.100068","article-title":"Genomic analysis of cutaneous CD30-positive lymphoproliferative disorders","volume":"2","author":"Abdulla","year":"2022","journal-title":"JID Innov"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105693_bib39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"18","key":"10.1016\/j.ebiom.2025.105693_bib40","first-page":"2194","article-title":"Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL","volume":"141","author":"Ruan","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105693_bib41","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/s41375-022-01571-8","article-title":"Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma","volume":"36","author":"Wong","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105693_bib42","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2017.182444","article-title":"Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified","volume":"103","author":"Ji","year":"2018","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.ebiom.2025.105693_bib43","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1200\/JCO.23.01687","article-title":"Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated peripheral T-cell lymphoma: final analysis of the ro-CHOP trial","volume":"42","author":"Camus","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105693_bib44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00280-023-04609-5","article-title":"The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis","volume":"93","author":"Tonozuka","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"10.1016\/j.ebiom.2025.105693_bib45","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1073\/pnas.1700682114","article-title":"Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1\/STAT3 mutations","volume":"114","author":"Chen","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105693_bib46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2133.2007.08427.x","article-title":"Potential involvement of Notch 1 signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders","volume":"158","author":"Kamstrup","year":"2008","journal-title":"Br J Dermatol"},{"issue":"20","key":"10.1016\/j.ebiom.2025.105693_bib47","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1158\/0008-5472.CAN-22-1215","article-title":"Notch signaling promotes mature T-cell lymphomagenesis","volume":"82","author":"Gao","year":"2022","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105693_bib48","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.3324\/haematol.2021.280003","article-title":"Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T\/NK-cell lymphoma from ENKTL and PTCL-NOS","volume":"107","author":"Wai","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105693_bib49","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/PAS.0000000000002184","article-title":"EBV-positive nodal T-cell and NK-cell lymphoma: a study of 26 cases including a subset with strong CD30 expression mimicking anaplastic large cell lymphoma","volume":"48","author":"Yu","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105693_bib50","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105693_bib51","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"M\u00fcller","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105693_bib52","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.annonc.2023.08.013","article-title":"Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas","volume":"34","author":"Song","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105693_bib53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ebiom.2025.105693_bib54","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105693_bib55","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1073\/pnas.1524668113","article-title":"Augmented efficacy of brentuximab vedotin combined with ruxolitinib and\/or Navitoclax in a murine model of human Hodgkin's lymphoma","volume":"113","author":"Ju","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"10.1016\/j.ebiom.2025.105693_bib56","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2013-10-534693","article-title":"SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ebiom.2025.105693_bib57","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood.2019000626","article-title":"Recurrent MSC (E116K) mutations in ALK-negative anaplastic large cell lymphoma","volume":"133","author":"Luchtel","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105693_bib58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.15778","article-title":"Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions","volume":"185","author":"Lees","year":"2019","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105693_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082294","article-title":"SP8 promotes an aggressive phenotype in hepatoblastoma via FGF8 activation","volume":"12","author":"Wagner","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105693_bib60","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105693_bib61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab vedotin-driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105693_bib62","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","article-title":"Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"issue":"33","key":"10.1016\/j.ebiom.2025.105693_bib63","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105693_bib64","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425001379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425001379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T16:18:14Z","timestamp":1762618694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425001379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":64,"alternative-id":["S2352396425001379"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105693","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular heterogeneity of CD30+ peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre study","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105693"}}